Pancreatitis Trial, Recruiting (NCT05146336)

Pancreatitis Trial, Recruiting NCT05146336 Sponsor: CytoSorbents, Inc Condition: Pancreatitis

Printed from Voxsanity (voxsanity.com.au) — NCT05146336 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pancreatitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are either already using, or your doctors are planning for you to use, a specific medical device called CytoSorb® 300 mL (a blood-filtering device).
You are willing and able to give your written agreement (consent) to take part in this registry study.

Who may not be able to join:

The CytoSorb® 300 mL device is being used only to remove blood-thinning medications from your body (rather than for other treatment purposes).
The CytoSorb® 300 mL device is being used only during heart surgery in the operating room, and not for any other purpose.
After you have already given your consent to join, a complication or medical situation arises that means the CytoSorb® 300 mL device is no longer safe or suitable for you to use (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ricard Ferrer Roca, MD, Hospital Vall d'Hebron

Phone: +49 30 654 99 145

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05146336

Sponsor: CytoSorbents, Inc

Phase: Not Applicable

Status: Recruiting

Condition: Pancreatitis

Trial contact: +49 30 654 99 145

More information: https://clinicaltrials.gov/study/NCT05146336

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are either already using, or your doctors are planning for you to use, a specific medical device called CytoSorb® 300 mL (a blood-filtering device).
You are willing and able to give your written agreement (consent) to take part in this registry study.

Who may not be able to join:

The CytoSorb® 300 mL device is being used only to remove blood-thinning medications from your body (rather than for other treatment purposes).
The CytoSorb® 300 mL device is being used only during heart surgery in the operating room, and not for any other purpose.
After you have already given your consent to join, a complication or medical situation arises that means the CytoSorb® 300 mL device is no longer safe or suitable for you to use (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

CytoSorbents, Inc

Registry

ClinicalTrials.gov

Start date

22 June 2022

Est. completion

1 June 2032

Where this trial is recruiting

🇦🇹 Austria 🇩🇪 Germany 🇮🇹 Italy 🇵🇱 Poland 🇵🇹 Portugal 🇪🇸 Spain

Primary endpoints

ICU mortality; In-hospital mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov